Drugs / 89Zr-Girentuximab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05046665 | May 2021 → Aug 2022 | urothelial carcinoma | South Metropolitan Health Service | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07077083 | Mar 2026 → Aug 2027 expected | clear cell renal carcinoma | Massachusetts General Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-Girentuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05046665 ↗ |
| Known as | 89Zr-TLX250 | “89Zirconium-labelled girentuximab (89Zr-TLX250) may have utility in the accurate staging of bladder and urothelial carcinomas, with less renal excretion as compared with FDG;...” PMID 35428649 ↗ Apr 2022 |